Nebulized Colistin in the Treatment of Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa
Clinical Infectious Diseases2005Vol. 41(5), pp. 754–757
Citations Over TimeTop 10% of 2005 papers
Abstract
Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies.
Related Papers
- → An Update on the arsenal for multidrug-resistant Acinetobacter infections: Polymyxin antibiotics(2014)58 cited
- → Activity of Polymyxin B and the Novel Polymyxin Analogue CB-182,804 Against Contemporary Gram-Negative Pathogens in New York City(2011)39 cited
- → Performances of the Rapid Polymyxin Acinetobacter and Pseudomonas Tests for Colistin Susceptibility Testing(2018)13 cited
- → Colistin, Polymyxin B and Tigecycline Suspectibility to Metallo Betalactamase Producing <i>Acinetobacter Baumannii</i> Isolated From Tertiary Health Care Hospital(2014)5 cited
- → RapidResa Polymyxin Acinetobacter NP® Test for Rapid Detection of Polymyxin Resistance in Acinetobacter baumannii(2021)4 cited